Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study will test the efficacy of naltrexone HCI and bupropion HCI (NB) versus placebo in
patients with binge-eating disorder (BED), with or without obesity.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Bupropion Bupropion hydrochloride, naltrexone hydrochoride drug combination Naltrexone